Enlivex Ltd.
Business
Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company developing Allocetra™, an off-the-shelf cell therapy that reprograms macrophages to restore immune homeostasis. It focuses on Allocetra™ as its primary product candidate for inflammatory and life‑threatening conditions, including osteoarthritis and sepsis, delivered via intra‑articular injections or intravenous infusions. The company conducts clinical development, cGMP manufacturing of frozen Allocetra™, and manages intellectual property and CRO collaborations. Enlivex runs multi‑center trials in Israel, Europe and the U.S. and plans commercialization via strategic partnerships and licensing.
Summary from filing dated 2025-04-30
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $1.24B |
| Total assets | $2.33B |
| Total liabilities | $392.05M |
| Stockholders' equity | $1.93B |
| Operating cash flow | $-10.42M |